{"title":"Retatrutide","description":null,"products":[{"product_id":"retatrutide-24mg-10-vials","title":"Retatrutide – 24mg (10 Vials)","description":"\u003cdiv class=\"plp-desc-rt\"\u003e\n\u003cstyle\u003e\n.plp-desc-rt{font-family:var(--font-body-family,Helvetica,Arial,sans-serif);color:rgba(18,18,18,.7)}\n.plp-desc-rt p{margin:0 0 15px;font-size:15.5px;font-weight:400;line-height:1.7}\n.plp-desc-rt strong{color:#0e2a44;font-weight:600}\n.plp-desc-rt em{color:rgba(18,18,18,.5)}\n.plp-desc-rt sup{line-height:0}\n.plp-desc-rt sup a{font-size:11px;font-weight:600;color:#2279be;text-decoration:none;padding:0 1px}\n.plp-desc-rt sup a:hover{color:#0e2a44}\n\u003c\/style\u003e\n\u003cp\u003e\u003cstrong\u003eRetatrutide\u003c\/strong\u003e is a first-in-class \u003cstrong\u003etriple receptor agonist\u003c\/strong\u003e — a single molecule that activates the \u003cstrong\u003eGIP\u003c\/strong\u003e, \u003cstrong\u003eGLP-1\u003c\/strong\u003e and \u003cstrong\u003eglucagon\u003c\/strong\u003e receptors at once. The added glucagon arm is thought to raise \u003cstrong\u003eenergy expenditure\u003c\/strong\u003e on top of the appetite reduction driven by GIP and GLP-1\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1016\/j.cmet.2022.07.013\" target=\"_blank\" rel=\"noopener\"\u003e[3]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eIn a 48-week \u003cstrong\u003ePhase 2 obesity trial\u003c\/strong\u003e, participants on the 12 mg dose recorded a mean \u003cstrong\u003ebody-weight reduction of 24.2%\u003c\/strong\u003e, versus 2.1% on placebo\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2301972\" target=\"_blank\" rel=\"noopener\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e. \u003cstrong\u003e83%\u003c\/strong\u003e of that group lost 15% or more of their body weight, and \u003cstrong\u003e93%\u003c\/strong\u003e lost at least 10%\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2301972\" target=\"_blank\" rel=\"noopener\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eIn a separate \u003cstrong\u003ePhase 2 type-2-diabetes trial\u003c\/strong\u003e, retatrutide lowered HbA1c by up to \u003cstrong\u003e2.02 points\u003c\/strong\u003e and cut body weight by about \u003cstrong\u003e16.9%\u003c\/strong\u003e at 36 weeks — outperforming the GLP-1 agonist dulaglutide\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1016\/S0140-6736(23)01053-X\" target=\"_blank\" rel=\"noopener\"\u003e[2]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eSupplied as ten \u003cstrong\u003elyophilized-powder\u003c\/strong\u003e vials for reconstitution — a research-quantity pack. \u003cem\u003eFigures above summarize published clinical findings on the retatrutide molecule and are provided as scientific reference for laboratory research only.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/div\u003e","brand":"Ziol ","offers":[{"title":"Default Title","offer_id":53712750248160,"sku":"RT26-A-10","price":1300.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0803\/9641\/9296\/files\/SUBSTITUA_A_LOGO_DA_PRIMELUB_POR_ESSA_QUE_EU_MANDEI_POR_FAVOR_3.png?v=1785272293"},{"product_id":"retatrutide-12mg-10-vials","title":"Retatrutide – 12mg (10 Vials)","description":"\u003cdiv class=\"plp-desc-rt\"\u003e\n\u003cstyle\u003e\n.plp-desc-rt{font-family:var(--font-body-family,Helvetica,Arial,sans-serif);color:rgba(18,18,18,.7)}\n.plp-desc-rt p{margin:0 0 15px;font-size:15.5px;font-weight:400;line-height:1.7}\n.plp-desc-rt strong{color:#0e2a44;font-weight:600}\n.plp-desc-rt em{color:rgba(18,18,18,.5)}\n.plp-desc-rt sup{line-height:0}\n.plp-desc-rt sup a{font-size:11px;font-weight:600;color:#2279be;text-decoration:none;padding:0 1px}\n.plp-desc-rt sup a:hover{color:#0e2a44}\n\u003c\/style\u003e\n\u003cp\u003e\u003cstrong\u003eRetatrutide\u003c\/strong\u003e is a first-in-class \u003cstrong\u003etriple receptor agonist\u003c\/strong\u003e — a single molecule that activates the \u003cstrong\u003eGIP\u003c\/strong\u003e, \u003cstrong\u003eGLP-1\u003c\/strong\u003e and \u003cstrong\u003eglucagon\u003c\/strong\u003e receptors at once. The added glucagon arm is thought to raise \u003cstrong\u003eenergy expenditure\u003c\/strong\u003e on top of the appetite reduction driven by GIP and GLP-1\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1016\/j.cmet.2022.07.013\" target=\"_blank\" rel=\"noopener\"\u003e[3]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eIn a 48-week \u003cstrong\u003ePhase 2 obesity trial\u003c\/strong\u003e, participants on the 12 mg dose recorded a mean \u003cstrong\u003ebody-weight reduction of 24.2%\u003c\/strong\u003e, versus 2.1% on placebo\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2301972\" target=\"_blank\" rel=\"noopener\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e. \u003cstrong\u003e83%\u003c\/strong\u003e of that group lost 15% or more of their body weight, and \u003cstrong\u003e93%\u003c\/strong\u003e lost at least 10%\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2301972\" target=\"_blank\" rel=\"noopener\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eIn a separate \u003cstrong\u003ePhase 2 type-2-diabetes trial\u003c\/strong\u003e, retatrutide lowered HbA1c by up to \u003cstrong\u003e2.02 points\u003c\/strong\u003e and cut body weight by about \u003cstrong\u003e16.9%\u003c\/strong\u003e at 36 weeks — outperforming the GLP-1 agonist dulaglutide\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1016\/S0140-6736(23)01053-X\" target=\"_blank\" rel=\"noopener\"\u003e[2]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eSupplied as ten \u003cstrong\u003elyophilized-powder\u003c\/strong\u003e vials for reconstitution — a research-quantity pack. \u003cem\u003eFigures above summarize published clinical findings on the retatrutide molecule and are provided as scientific reference for laboratory research only.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/div\u003e","brand":"Ziol ","offers":[{"title":"Default Title","offer_id":53712750215392,"sku":"RT14-A-10","price":875.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0803\/9641\/9296\/files\/3_ddeeb1fe-01bf-4084-98b4-65dd12ec920f.png?v=1785270009"},{"product_id":"retatrutide-6mg-10-vials","title":"Retatrutide – 6mg (10 Vials)","description":"\u003cstyle\u003e\n.plp-desc-rt{font-family:var(--font-body-family,Helvetica,Arial,sans-serif);color:rgba(18,18,18,.7)}\n.plp-desc-rt p{margin:0 0 15px;font-size:15.5px;font-weight:400;line-height:1.7}\n.plp-desc-rt strong{color:#0e2a44;font-weight:600}\n.plp-desc-rt em{color:rgba(18,18,18,.5)}\n.plp-desc-rt sup{line-height:0}\n.plp-desc-rt sup a{font-size:11px;font-weight:600;color:#2279be;text-decoration:none;padding:0 1px}\n.plp-desc-rt sup a:hover{color:#0e2a44}\n\u003c\/style\u003e\n\u003cdiv class=\"plp-desc-rt\"\u003e\n\u003cp\u003e\u003cstrong\u003eRetatrutide\u003c\/strong\u003e is a first-in-class \u003cstrong\u003etriple receptor agonist\u003c\/strong\u003e — a single molecule that activates the \u003cstrong\u003eGIP\u003c\/strong\u003e, \u003cstrong\u003eGLP-1\u003c\/strong\u003e and \u003cstrong\u003eglucagon\u003c\/strong\u003e receptors at once. The added glucagon arm is thought to raise \u003cstrong\u003eenergy expenditure\u003c\/strong\u003e on top of the appetite reduction driven by GIP and GLP-1\u003csup\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eIn a 48-week \u003cstrong\u003ePhase 2 obesity trial\u003c\/strong\u003e, participants on the 12 mg dose recorded a mean \u003cstrong\u003ebody-weight reduction of 24.2%\u003c\/strong\u003e, versus 2.1% on placebo\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2301972\" rel=\"noopener\" target=\"_blank\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e. \u003cstrong\u003e83%\u003c\/strong\u003e of that group lost 15% or more of their body weight, and \u003cstrong\u003e93%\u003c\/strong\u003e lost at least 10%\u003csup\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eIn a separate \u003cstrong\u003ePhase 2 type-2-diabetes trial\u003c\/strong\u003e, retatrutide lowered HbA1c by up to \u003cstrong\u003e2.02 points\u003c\/strong\u003e and cut body weight by about \u003cstrong\u003e16.9%\u003c\/strong\u003e at 36 weeks — outperforming the GLP-1 agonist dulaglutide\u003csup\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eSupplied as ten \u003cstrong\u003elyophilized-powder\u003c\/strong\u003e vials for reconstitution — a research-quantity pack. \u003cem\u003eFigures above summarize published clinical findings on the retatrutide molecule and are provided as scientific reference for laboratory research only.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/div\u003e","brand":"Ziol ","offers":[{"title":"Default Title","offer_id":53712750313696,"sku":"RT7-A-10","price":592.5,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0803\/9641\/9296\/files\/SUBSTITUAALOGODAPRIMELUBPORESSAQUEEUMANDEIPORFAVOR_2.png?v=1785272086"},{"product_id":"retatrutide-24mg","title":"Retatrutide – 24mg","description":"\u003cdiv class=\"plp-desc-rt\"\u003e\n\u003cstyle\u003e\n.plp-desc-rt{font-family:var(--font-body-family,Helvetica,Arial,sans-serif);color:rgba(18,18,18,.7)}\n.plp-desc-rt p{margin:0 0 15px;font-size:15.5px;font-weight:400;line-height:1.7}\n.plp-desc-rt strong{color:#0e2a44;font-weight:600}\n.plp-desc-rt em{color:rgba(18,18,18,.5)}\n.plp-desc-rt sup{line-height:0}\n.plp-desc-rt sup a{font-size:11px;font-weight:600;color:#2279be;text-decoration:none;padding:0 1px}\n.plp-desc-rt sup a:hover{color:#0e2a44}\n\u003c\/style\u003e\n\u003cp\u003e\u003cstrong\u003eRetatrutide\u003c\/strong\u003e is a first-in-class \u003cstrong\u003etriple receptor agonist\u003c\/strong\u003e — a single molecule that activates the \u003cstrong\u003eGIP\u003c\/strong\u003e, \u003cstrong\u003eGLP-1\u003c\/strong\u003e and \u003cstrong\u003eglucagon\u003c\/strong\u003e receptors at once. The added glucagon arm is thought to raise \u003cstrong\u003eenergy expenditure\u003c\/strong\u003e on top of the appetite reduction driven by GIP and GLP-1\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1016\/j.cmet.2022.07.013\" target=\"_blank\" rel=\"noopener\"\u003e[3]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eIn a 48-week \u003cstrong\u003ePhase 2 obesity trial\u003c\/strong\u003e, participants on the 12 mg dose recorded a mean \u003cstrong\u003ebody-weight reduction of 24.2%\u003c\/strong\u003e, versus 2.1% on placebo\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2301972\" target=\"_blank\" rel=\"noopener\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e. \u003cstrong\u003e83%\u003c\/strong\u003e of that group lost 15% or more of their body weight, and \u003cstrong\u003e93%\u003c\/strong\u003e lost at least 10%\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2301972\" target=\"_blank\" rel=\"noopener\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eIn a separate \u003cstrong\u003ePhase 2 type-2-diabetes trial\u003c\/strong\u003e, retatrutide lowered HbA1c by up to \u003cstrong\u003e2.02 points\u003c\/strong\u003e and cut body weight by about \u003cstrong\u003e16.9%\u003c\/strong\u003e at 36 weeks — outperforming the GLP-1 agonist dulaglutide\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1016\/S0140-6736(23)01053-X\" target=\"_blank\" rel=\"noopener\"\u003e[2]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eSupplied as a \u003cstrong\u003elyophilized powder\u003c\/strong\u003e for reconstitution. \u003cem\u003eFigures above summarize published clinical findings on the retatrutide molecule and are provided as scientific reference for laboratory research only.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/div\u003e","brand":"Ziol ","offers":[{"title":"Default Title","offer_id":53712750641376,"sku":"RT26-A","price":195.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0803\/9641\/9296\/files\/SUBSTITUA_A_LOGO_DA_PRIMELUB_POR_ESSA_QUE_EU_MANDEI_POR_FAVOR_3.png?v=1785272293"},{"product_id":"retatrutide-12mg","title":"Retatrutide – 12mg","description":"\u003cstyle\u003e\n.plp-desc-rt{font-family:var(--font-body-family,Helvetica,Arial,sans-serif);color:rgba(18,18,18,.7)}\n.plp-desc-rt p{margin:0 0 15px;font-size:15.5px;font-weight:400;line-height:1.7}\n.plp-desc-rt strong{color:#0e2a44;font-weight:600}\n.plp-desc-rt em{color:rgba(18,18,18,.5)}\n.plp-desc-rt sup{line-height:0}\n.plp-desc-rt sup a{font-size:11px;font-weight:600;color:#2279be;text-decoration:none;padding:0 1px}\n.plp-desc-rt sup a:hover{color:#0e2a44}\n\u003c\/style\u003e\n\u003cdiv class=\"plp-desc-rt\"\u003e\n\u003cp\u003e\u003cstrong\u003eRetatrutide\u003c\/strong\u003e is a first-in-class \u003cstrong\u003etriple receptor agonist\u003c\/strong\u003e — a single molecule that activates the \u003cstrong\u003eGIP\u003c\/strong\u003e, \u003cstrong\u003eGLP-1\u003c\/strong\u003e and \u003cstrong\u003eglucagon\u003c\/strong\u003e receptors at once. The added glucagon arm is thought to raise \u003cstrong\u003eenergy expenditure\u003c\/strong\u003e on top of the appetite reduction driven by GIP and GLP-1\u003csup\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eIn a 48-week \u003cstrong\u003ePhase 2 obesity trial\u003c\/strong\u003e, participants on the 12 mg dose recorded a mean \u003cstrong\u003ebody-weight reduction of 24.2%\u003c\/strong\u003e, versus 2.1% on placebo\u003csup\u003e\u003c\/sup\u003e. \u003cstrong\u003e83%\u003c\/strong\u003e of that group lost 15% or more of their body weight, and \u003cstrong\u003e93%\u003c\/strong\u003e lost at least 10%\u003csup\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eIn a separate \u003cstrong\u003ePhase 2 type-2-diabetes trial\u003c\/strong\u003e, retatrutide lowered HbA1c by up to \u003cstrong\u003e2.02 points\u003c\/strong\u003e and cut body weight by about \u003cstrong\u003e16.9%\u003c\/strong\u003e at 36 weeks — outperforming the GLP-1 agonist dulaglutide\u003csup\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eSupplied as a \u003cstrong\u003elyophilized powder\u003c\/strong\u003e for reconstitution. \u003cem\u003eFigures above summarize published clinical findings on the retatrutide molecule and are provided as scientific reference for laboratory research only.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/div\u003e","brand":"Ziol ","offers":[{"title":"Default Title","offer_id":53712750706912,"sku":"RT14-A","price":150.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0803\/9641\/9296\/files\/3_ddeeb1fe-01bf-4084-98b4-65dd12ec920f.png?v=1785270009"},{"product_id":"retatrutide-6mg","title":"Retatrutide – 6mg","description":"\u003cstyle\u003e\n.plp-desc-rt{font-family:var(--font-body-family,Helvetica,Arial,sans-serif);color:rgba(18,18,18,.7)}\n.plp-desc-rt p{margin:0 0 15px;font-size:15.5px;font-weight:400;line-height:1.7}\n.plp-desc-rt strong{color:#0e2a44;font-weight:600}\n.plp-desc-rt em{color:rgba(18,18,18,.5)}\n.plp-desc-rt sup{line-height:0}\n.plp-desc-rt sup a{font-size:11px;font-weight:600;color:#2279be;text-decoration:none;padding:0 1px}\n.plp-desc-rt sup a:hover{color:#0e2a44}\n\u003c\/style\u003e\n\u003cdiv class=\"plp-desc-rt\"\u003e\n\u003cp\u003e\u003cstrong\u003eRetatrutide\u003c\/strong\u003e is a first-in-class \u003cstrong\u003etriple receptor agonist\u003c\/strong\u003e — a single molecule that activates the \u003cstrong\u003eGIP\u003c\/strong\u003e, \u003cstrong\u003eGLP-1\u003c\/strong\u003e and \u003cstrong\u003eglucagon\u003c\/strong\u003e receptors at once. The added glucagon arm is thought to raise \u003cstrong\u003eenergy expenditure\u003c\/strong\u003e on top of the appetite reduction driven by GIP and GLP-1\u003csup\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eIn a 48-week \u003cstrong\u003ePhase 2 obesity trial\u003c\/strong\u003e, participants on the 12 mg dose recorded a mean \u003cstrong\u003ebody-weight reduction of 24.2%\u003c\/strong\u003e, versus 2.1% on placebo. \u003csup\u003e\u003c\/sup\u003e\u003cstrong\u003e83%\u003c\/strong\u003e of that group lost 15% or more of their body weight, and \u003cstrong\u003e93%\u003c\/strong\u003e lost at least 10%.\u003c\/p\u003e\n\u003cp\u003eIn a separate \u003cstrong\u003ePhase 2 type-2-diabetes trial\u003c\/strong\u003e, retatrutide lowered HbA1c by up to \u003cstrong\u003e2.02 points\u003c\/strong\u003e and cut body weight by about \u003cstrong\u003e16.9%\u003c\/strong\u003e at 36 weeks — outperforming the GLP-1 agonist dulaglutide\u003csup\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eSupplied as a \u003cstrong\u003elyophilized powder\u003c\/strong\u003e for reconstitution. \u003cem\u003eFigures above summarize published clinical findings on the retatrutide molecule and are provided as scientific reference for laboratory research only.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/div\u003e","brand":"Ziol ","offers":[{"title":"Default Title","offer_id":53712750739680,"sku":"RT7-A","price":90.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0803\/9641\/9296\/files\/SUBSTITUAALOGODAPRIMELUBPORESSAQUEEUMANDEIPORFAVOR_2.png?v=1785272086"}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0803\/9641\/9296\/collections\/SUBSTITUA_A_LOGO_DA_PRIMELUB_POR_ESSA_QUE_EU_MANDEI_POR_FAVOR_3.png?v=1785335511","url":"https:\/\/ziol.shop\/collections\/retatrutide.oembed","provider":"Ziol ","version":"1.0","type":"link"}